Analysis of the UK Government's 10-Year Drugs Strategy-a resource for practitioners and policymakers.


Journal

Journal of public health (Oxford, England)
ISSN: 1741-3850
Titre abrégé: J Public Health (Oxf)
Pays: England
ID NLM: 101188638

Informations de publication

Date de publication:
14 Jun 2023
Historique:
received: 01 06 2022
revised: 10 08 2022
medline: 19 6 2023
pubmed: 31 10 2022
entrez: 30 10 2022
Statut: ppublish

Résumé

In 2021, during a drug-related death crisis in the UK, the Government published its ten-year drugs strategy. This article, written in collaboration with the Faculty of Public Health and the Association of Directors of Public Health, assesses whether this Strategy is evidence-based and consistent with international calls to promote public health approaches to drugs, which put 'people, health and human rights at the centre'. Elements of the Strategy are welcome, including the promise of significant funding for drug treatment services, the effects of which will depend on how it is utilized by services and local commissioners and whether it is sustained. However, unevidenced and harmful measures to deter drug use by means of punishment continue to be promoted, which will have deleterious impacts on people who use drugs. An effective public health approach to drugs should tackle population-level risk factors, which may predispose to harmful patterns of drug use, including adverse childhood experiences and socioeconomic deprivation, and institute evidence-based measures to mitigate drug-related harm. This would likely be more effective, and just, than the continuation of policies rooted in enforcement. A more dramatic re-orientation of UK drug policy than that offered by the Strategy is overdue.

Identifiants

pubmed: 36309802
pii: 6779883
doi: 10.1093/pubmed/fdac114
pmc: PMC10273368
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e215-e224

Subventions

Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Faculty of Public Health.

Références

Arch Gen Psychiatry. 2001 May;58(5):503-8
pubmed: 11343531
PLoS One. 2022 Jan 12;17(1):e0261885
pubmed: 35020763
Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35
pubmed: 23490450
Soc Sci Med. 2020 Sep;260:113183
pubmed: 32682207
Lancet Public Health. 2022 Feb;7(2):e126-e135
pubmed: 34906332
J Hepatol. 2022 Mar;76(3):549-557
pubmed: 34634387
Int J Drug Policy. 2021 Sep;95:103270
pubmed: 33972157
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732
Addiction. 2003 Jan;98(1):83-91
pubmed: 12492758
Lancet Psychiatry. 2022 Feb;9(2):151-159
pubmed: 34921800
Int J Drug Policy. 2011 Mar;22(2):87-94
pubmed: 21392957
Drug Alcohol Rev. 2022 Jan;41(1):54-61
pubmed: 33960031
Drug Alcohol Depend. 2005 Aug 1;79(2):231-40
pubmed: 16002032
Int J Drug Policy. 2015 Jan;26(1):51-8
pubmed: 25444768
BMC Public Health. 2017 Feb 3;17(1):163
pubmed: 28158995
PLoS One. 2014 Apr 02;9(4):e91936
pubmed: 24694747
J Infect Dis. 2018 May 25;217(12):1875-1882
pubmed: 29546333
Lancet. 2010 Aug 7;376(9739):475-85
pubmed: 20650514
Addiction. 2017 Aug;112(8):1408-1418
pubmed: 28160345
Int J Drug Policy. 2021 Dec;98:103391
pubmed: 34343945
Addiction. 2012 Sep;107(9):1539-40
pubmed: 22509981
JAMA Psychiatry. 2021 Sep 1;78(9):979-993
pubmed: 34076676
Int J Drug Policy. 2022 Nov;109:103840
pubmed: 36068144
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
Addiction. 2018 Aug;113(8):1461-1476
pubmed: 29672985
Int J Drug Policy. 2021 Oct;96:103286
pubmed: 34011449
Addiction. 2019 Sep;114(9):1602-1613
pubmed: 31166621
BMJ. 2010 Oct 26;341:c5475
pubmed: 20978062
Lancet Public Health. 2022 Mar;7(3):e196-e197
pubmed: 35247348
Addiction. 2022 May;117(5):1338-1352
pubmed: 34729841
Lancet Public Health. 2018 Dec;3(12):e567-e575
pubmed: 30389570
Int J Drug Policy. 2018 Jun;56:187-196
pubmed: 29459212
J Viral Hepat. 2019 May;26(5):541-551
pubmed: 30663179
N Engl J Med. 2007 Jan 11;356(2):157-65
pubmed: 17215533
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Am J Public Health. 2012 Dec;102(12):e67-75
pubmed: 23078476
BMJ. 1998 Feb 7;316(7129):426-8
pubmed: 9492665
Int J Drug Policy. 2022 Jun;104:103670
pubmed: 35523063
J Public Health (Oxf). 2020 Nov 23;42(4):e487-e495
pubmed: 31883007
BMJ Open. 2020 Sep 21;10(9):e035148
pubmed: 32958480
Addiction. 2018 Dec;113(12):2155-2157
pubmed: 29953686
Neuropsychopharmacology. 2016 Feb;41(3):762-73
pubmed: 26171718
Br J Psychiatry. 2015 Jul;207(1):5-14
pubmed: 26135571
JAMA Psychiatry. 2020 May 1;77(5):493-502
pubmed: 31876906
Harm Reduct J. 2020 Jul 31;17(1):53
pubmed: 32736624
Int J Drug Policy. 2020 Sep;83:102829
pubmed: 32595070
Int J Drug Policy. 2019 Apr;66:94-99
pubmed: 30776759
PLoS Med. 2021 Oct 5;18(10):e1003759
pubmed: 34610017
Drug Alcohol Rev. 2007 Jul;26(4):379-87
pubmed: 17564873
BMC Public Health. 2014 Aug 16;14:853
pubmed: 25128331
Addiction. 2021 Oct;116(10):2893-2907
pubmed: 33651446
Addiction. 2015 May;110(5):805-20
pubmed: 25559418
Am J Epidemiol. 2013 Apr 1;177(7):675-82
pubmed: 23445901
Addiction. 2017 Aug;112(8):1329-1336
pubmed: 28044376
Aliment Pharmacol Ther. 2022 Mar;55(5):568-579
pubmed: 34877667
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
Lancet Public Health. 2022 Feb;7(2):e136-e145
pubmed: 35012711
BMC Med. 2019 Feb 15;17(1):31
pubmed: 30764826
Addiction. 2016 Feb;111(2):298-308
pubmed: 26452239
PLoS Med. 2019 Nov 26;16(11):e1002965
pubmed: 31770388
Int J Drug Policy. 2016 Feb;28:1-9
pubmed: 26790691
Addiction. 2022 Mar;117(3):532-544
pubmed: 34729849
Nat Rev Dis Primers. 2020 Jan 9;6(1):3
pubmed: 31919349
BMJ. 2020 Feb 24;368:m693
pubmed: 32094110
BMJ. 2010 Jul 01;341:c3172
pubmed: 20595255
Addiction. 2017 Sep;112(9):1580-1589
pubmed: 28493329
J Viral Hepat. 2021 Oct;28(10):1452-1463
pubmed: 34270172
Lancet Psychiatry. 2021 Apr;8(4):301-309
pubmed: 33640039
Subst Abuse Treat Prev Policy. 2012 Nov 24;7:47
pubmed: 23176382
Int J Drug Policy. 2022 Feb;100:103512
pubmed: 34753047
BMC Med. 2022 Apr 14;20(1):151
pubmed: 35418095

Auteurs

Adam Holland (A)

Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK.

Alex Stevens (A)

School of Social Policy, Sociology and Social Research, University of Kent, Canterbury, CT2 7NZ.

Magdalena Harris (M)

Department of Public Health, Environments and Society, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK.

Dan Lewer (D)

Public Health Specialty Registrar, Department of Epidemiology and Public Health, University College London, London, WC1E 6BT, UK.

Harry Sumnall (H)

Public Health Institute, Liverpool John Moores University, Liverpool, L3 5UX, UK.

Daniel Stewart (D)

Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK.

Eilish Gilvarry (E)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, NE1 7RU, UK.

Alice Wiseman (A)

Association of Directors of Public Health, London, EC4Y 0HA, UK.

Joshua Howkins (J)

Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK.

Jim McManus (J)

Association of Directors of Public Health, London, EC4Y 0HA, UK.

Gillian W Shorter (GW)

School of Psychology, Queen's University Belfast, Belfast, BT7 1NN.

James Nicholls (J)

Faculty of Health Sciences and Sport, University of Stirling, Stirling, FK9 4LA, UK.

Jenny Scott (J)

Department of Pharmacy & Pharmacology, University of Bath, Bath, BA2 7AY.

Kyla Thomas (K)

Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK.

Leila Reid (L)

Hepatitis C Trust, London, SE1 3YD, UK.

Edward Day (E)

Institute of Mental Health, University of Birmingham, Birmingham, B15 2TT.

Jason Horsley (J)

National Institute for Health Research Evaluation Trials and Studies Coordinating Centre, University of Southampton, Southampton, SO17 1BJ, UK.

Fiona Measham (F)

Department of Sociology, Social Policy and Criminology, University of Liverpool, Liverpool, L69 3BX.

Maggie Rae (M)

Epidemiological and Public Health Section, Royal Society of Medicine, London, W1G 0AE, UK.

Kevin Fenton (K)

Faculty of Public Health, London, NW1 4LB, UK.

Matthew Hickman (M)

Bristol Medical School, University of Bristol, Bristol, BS8 2BN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH